High- and intermediate-risk types of human papillomavirus (HPV) in concert with cofactors are responsible for over 90% of cervical cancers world-wide. While the Pap smear is a valuable cancer prevention tool, its subjective nature leaves it error prone. As a result, HPV DNA testing appears to be a needed adjunct to the Pap smear. Hybrid Capture is a simple DNA test with high specificity and sensitivity which appears useful for clinical management of equivocal Pap tests and shows promise for mass screening.
No takes yet. Share an insight, caveat, or question.
Attila T. Lörincz (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: